Literature DB >> 17408229

Formulation development and in vitro and in vivo evaluation of membrane-moderated transdermal systems of ampicillin sodium in ethanol: pH 4.7 buffer solvent system.

Janardhanan Bagyalakshmi1, Ramachandra Purapu Vamsikrishna, Rajappan Manavalan, Thengungal Kochupappy Ravi, Probal Kumar Manna.   

Abstract

The objective of the present study was to develop membrane-moderated transdermal systems of ampicillin sodium and to evaluate them with respect to various in vitro and in vivo parameters. The membrane-type transdermal systems were prepared using a drug with various antinucleant polymers-hydroxypropyl methylcellulose (HPMC), methylcellulose (MC), cellulose acetate phthalate, chitosan, sodium alginate (SA), and sodium carboxymethylcellulose-in an ethanol: pH 4.7 buffer volatile system by the solvent evaporation technique with HPMC as the rate-controlling membrane for all the systems. The swelling properties of the polymers were studied, and drug-polymer interaction studies were performed. The patches were subjected to various physicochemical studies, in vitro release studies, permeation studies, and skin irritation studies. The best patch among the formulations was selected for further in vivo studies. Compared to the other patches, SA exhibited the highest moisture content at 16%; a 21% moisture uptake was found with MC. The release and permeation of the drug from the SA patch was found to be the maximum. The in vivo study of the SA patch exhibited a peak plasma concentration C(max) of 126 microg/mL at T(max) 4 hours. Hence, it can be concluded that hydrophilic ampicillin sodium can be developed as a transdermal delivery system with SA that is an alternative to intravenous administration and has minimal adverse effects.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17408229      PMCID: PMC2750442          DOI: 10.1208/pt0801007

Source DB:  PubMed          Journal:  AAPS PharmSciTech        ISSN: 1530-9932            Impact factor:   3.246


  17 in total

1.  Comparison of the antibacterial activities of ampicillin, ciprofloxacin, clarithromycin, telithromycin and quinupristin/dalfopristin against intracellular non-typeable Haemophilus influenzae.

Authors:  Irini Lazou Ahrén; Eva Karlsson; Arne Forsgren; Kristian Riesbeck
Journal:  J Antimicrob Chemother       Date:  2002-12       Impact factor: 5.790

2.  Enzymic degradation of a beta-lactam antibiotic, ampicillin, in the gut: a novel treatment modality.

Authors:  Jaana Harmoinen; Kirsi Vaali; Pertti Koski; Kaisa Syrjänen; Outi Laitinen; Kai Lindevall; Elias Westermarck
Journal:  J Antimicrob Chemother       Date:  2003-02       Impact factor: 5.790

3.  New vesicular ampicillin-loaded delivery systems for topical application: characterization, in vitro permeation experiments and antimicrobial activity.

Authors:  M Carafa; C Marianecci; G Lucania; E Marchei; E Santucci
Journal:  J Control Release       Date:  2004-02-20       Impact factor: 9.776

4.  Design and in vitro evaluation of new drug-in-adhesive formulations of fentanyl transdermal patches.

Authors:  Amir Mehdizadeh; Tayebe Toliate; Mohammad Reza Rouini; Sharyar Abashzadeh; Farid Dorkoosh
Journal:  Acta Pharm       Date:  2004-12       Impact factor: 2.230

5.  Network structure of cellulose ethers used in pharmaceutical applications during swelling and at equilibrium.

Authors:  Saia Baumgartner; Julijana Kristl; Nicholas A Peppas
Journal:  Pharm Res       Date:  2002-08       Impact factor: 4.200

6.  Delivery of erythromycin to subcutaneous tissues in rats by means of a trans-phase delivery system.

Authors:  L Peng; M E Nimni
Journal:  J Pharm Pharmacol       Date:  1999-10       Impact factor: 3.765

7.  Drug-induced interstitial nephritis with heavy glomerular proteinuria.

Authors:  H G Rennke; P C Roos; S G Wall
Journal:  N Engl J Med       Date:  1980-03-20       Impact factor: 91.245

8.  Acute interstitial nephritis due to drugs: Review of the literature with a report of nine cases.

Authors:  A L Linton; W F Clark; A A Driedger; D I Turnbull; R M Lindsay
Journal:  Ann Intern Med       Date:  1980-11       Impact factor: 25.391

9.  Design, development, physicochemical, and in vitro and in vivo evaluation of transdermal patches containing diclofenac diethylammonium salt.

Authors:  Priyanka Arora; Biswajit Mukherjee
Journal:  J Pharm Sci       Date:  2002-09       Impact factor: 3.534

10.  Formulation and evaluation of limonene-based membrane-moderated transdermal therapeutic system of nimodipine.

Authors:  Y S R Krishnaiah; P Bhaskar; V Satyanarayana
Journal:  Drug Deliv       Date:  2004 Jan-Feb       Impact factor: 6.419

View more
  5 in total

1.  Two-step solid lipid extrusion as a process to modify dissolution behavior.

Authors:  Maike Windbergs; Sinan Gueres; Clare J Strachan; Peter Kleinebudde
Journal:  AAPS PharmSciTech       Date:  2010-03-23       Impact factor: 3.246

2.  Dental mold: a novel formulation to treat common dental disorders.

Authors:  Soma Ghosh; Gopa Roy; Biswajit Mukherjee
Journal:  AAPS PharmSciTech       Date:  2009-05-23       Impact factor: 3.246

3.  Formulation design and development of matrix diffusion controlled transdermal drug delivery of glimepiride.

Authors:  Muhammad Rouf Akram; Mahmood Ahmad; Asad Abrar; Rai Muhammad Sarfraz; Asif Mahmood
Journal:  Drug Des Devel Ther       Date:  2018-02-21       Impact factor: 4.162

4.  Fabrication and Characterization of Chitosan-Tamarind Seed Polysaccharide Composite Film for Transdermal Delivery of Protein/Peptide.

Authors:  Rishabha Malviya; Anchal Tyagi; Shivkanya Fuloria; Vetriselvan Subramaniyan; Kathiresan Sathasivam; Sonali Sundram; Sundram Karupiah; Srikumar Chakravarthi; Dhanalekshmi Unnikrishnan Meenakshi; Nandan Gupta; Mahendran Sekar; Kalvatala Sudhakar; Neeraj Kumar Fuloria
Journal:  Polymers (Basel)       Date:  2021-05-10       Impact factor: 4.329

5.  Synthesis and Charactersiation of Chitosan conjugate; Design and Evaluation of Membrane Moderated Type Transdermal Drug Delivery System.

Authors:  B K Satheeshababu; R Shruthinag
Journal:  Indian J Pharm Sci       Date:  2015 Jul-Aug       Impact factor: 0.975

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.